Pharmasyntez plans massive expansion of portfolio of innovative drugs

21 May 2025

Pharmasyntez, one of Russia’s leading drugmakers, plans a significant expansion of its portfolio of innovative drugs in the short-term, according to recent statements, made by representatives of the company, reports The Pharma Letter’s local correspondent.

Vikram Punia, president of the company, said during the recent Semashko Russian Pharmaceutical Forum, one of Russia’s most important pharmaceutical forums, the company plans to launch at least three new drugs already in the middle term. One of such drugs will be a third-generation tyrosine kinase inhibitor (TKI) for the treatment of oncological blood diseases. Also, the company continues the development of drugs for the prevention of postoperative adhesions and treatment of type 2 diabetes.

Mr Punia also noted that the company’s investments in scientific research and the development of new drugs amount to billions of roubles annually, which allows it to continue the development of new drugs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK